JUL 23, 2026 · JOURNAL ARTICLE
A promising therapeutic strategy reduces abnormal Aβ deposition and inhibits neuronal apoptosis via FGF17 ameliorating AD-like neurodegeneration.
Brain Research
A mechanistic study in cell and transgenic mouse models showing FGF17 delivery reduces Aβ deposition and apoptosis with pathway confirmation, but lacking human efficacy data and powered clinical outcomes.
Reported
Primary biological observationsReduced FGF17 in AD serum, Aβ1-42-treated S…
Cognitive endpointAAV9-FGF17 delivery alleviated cognitive im…
Mechanistic pathwayFGFR3/PI3K/AKT signaling activation; FGFR3…